Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06065852
Other study ID # RaDaR
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 6, 2009
Est. completion date December 31, 2039

Study information

Verified date September 2023
Source UK Kidney Association
Contact Zoe Plummer
Email zoe.plummer@ukkidney.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research is to: - Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition. - Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better. - Further the development of future treatments. Participants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.


Description:

Background Rare diseases are arbitrarily defined as having an incidence such that they cannot be studied effectively on patient groups drawn from one or a few medical centres. A high proportion of such disorders have a genetic background and often these diseases are first expressed in childhood. The success of chronic and end-stage renal failure programmes in childhood permit increased numbers of these patients to survive into adulthood. There are 13 centres for paediatric nephrology in the UK. For a rare disorder that a paediatric nephrologist might diagnosis only once a year, and assuming 100% survival to adulthood, a renal physician might be asked to take over such a case only once in seven or eight years of practice. Research is hampered by this dilution of clinical experience. Similarly in adult practice there are rare complications of diseases or their treatment so that a nephrologist might encounter such an event less often than once in every 5 years. National aggregation of clinical experience is essential to further study. Research groups investigating a rare disease (Rare Disease Groups, RDGs) have difficulty accessing patients who are widely distributed. While rare disease groups are often successful in identifying novel genotypes in a few individuals, it is more difficult to define phenotype and undertake phenotype-genotype correlations. Moreover, the scarcity of patients makes it difficult to develop biomarkers or identify well-defined cohorts in which to test novel treatments. As a result, the progression and outcome for many rare diseases are unknown and treatment remains underdeveloped. Purpose The purpose of the National Registry of Rare Kidney Diseases (RaDaR; rare disease registry) is to facilitate translational and epidemiological research into rare kidney diseases by setting up and maintaining a comprehensive clinical database in partnership with Rare Disease Groups. RaDaR facilitates the identification of well-characterized cohorts of patients who may be invited to participate in clinical trials, the development of biomarkers, phenotype-genotype correlations or outcome studies. This will inform the development of clinical guidelines for specific rare diseases, audit treatment and outcome and further the development of future therapies. RaDaR provides an infrastructure to capture both generic and disease-specific clinical information and to collate longitudinal information. Patients and clinicians can view information about the conditions covered by RaDaR on RareRenal.org, which links closely with RaDaR. RaDaR is predominately aimed at UK patients; however international recruits who are consented in the UK by an NHS hospital are also eligible, subject to local approval.


Recruitment information / eligibility

Status Recruiting
Enrollment 35000
Est. completion date December 31, 2039
Est. primary completion date December 31, 2039
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility - Kidney Rare Disease - Paeds and adults - Eligibility differs for each rare disease group - See: https://ukkidney.org/rare-renal/recruitment

Study Design


Related Conditions & MeSH terms

  • Acidosis
  • Acidosis, Renal Tubular
  • Adenine Phosphoribosyltransferase Deficiency
  • AL Amyloidosis
  • Alport Syndrome
  • Amyloidosis
  • Arthrogryposis
  • Atypical Hemolytic Uremic Syndrome
  • Autosomal Dominant Polycystic Kidney Disease
  • Autosomal Recessive Polycystic Kidney Disease
  • Azotemia
  • Bartter Syndrome
  • BK Nephropathy
  • C3 Glomerulopathy
  • Calciphylaxis
  • Cystinosis
  • Cystinuria
  • Deafness
  • Dense Deposit Disease
  • Dent Disease
  • Denys-Drash Syndrome
  • Diabetes Insipidus
  • Diabetes Insipidus, Nephrogenic
  • Diabetes Mellitus
  • Fabry Disease
  • Familial Hypophosphatemic Rickets
  • Familial Renal Glucosuria
  • Fanconi Anemia
  • Fanconi Syndrome
  • Fibrillary Glomerulonephritis
  • Fibromuscular Dysplasia
  • Focal Segmental Glomerulosclerosis
  • Gitelman Syndrome
  • Glomerulonephritis
  • Glomerulonephritis, IGA
  • Glomerulonephritis, Membranoproliferative
  • Glomerulonephritis, Membranous
  • Glomerulosclerosis, Focal Segmental
  • Hearing Loss, Sensorineural
  • Hemolytic-Uremic Syndrome
  • Histiocytosis
  • Hypercalciuria
  • Hyperoxaluria, Primary
  • Hypocalcemia
  • Hypophosphatemia
  • IgA Nephropathy
  • Immunoglobulin Light-chain Amyloidosis
  • Inappropriate ADH Syndrome
  • Kidney Diseases
  • Kidney Neoplasms
  • Lowe Syndrome
  • Membranoproliferative Glomerulonephritis
  • Membranous Nephropathy
  • Mitochondrial Diseases
  • Monoclonal Gammopathy of Undetermined Significance
  • Nail Patella Syndrome
  • Nephritis, Hereditary
  • Nephrocalcinosis
  • Nephrogenic Diabetes Insipidus
  • Nephrolithiasis
  • Nephronophthisis
  • Nephrosis
  • Nephrosis, Lipoid
  • Nephrotic Syndrome
  • Oculocerebrorenal Syndrome
  • Osteoporosis
  • Paraproteinemias
  • Polycystic Kidney Diseases
  • Polycystic Kidney, Autosomal Dominant
  • Polycystic Kidney, Autosomal Recessive
  • Primary Hyperoxaluria
  • Pseudohypoaldosteronism
  • Pure Red Cell Aplasia
  • Red-Cell Aplasia, Pure
  • Retroperitoneal Fibrosis
  • Rickets
  • Sickle Cell Nephropathy
  • Steroid Resistant Nephrotic Syndrome
  • Steroid-Sensitive Nephrotic Syndrome
  • Syndrome
  • Thrombotic Microangiopathies
  • Tuberous Sclerosis
  • Vasculitis

Locations

Country Name City State
United Kingdom Zoe Plummer Bristol South West

Sponsors (1)

Lead Sponsor Collaborator
UK Kidney Association

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Facilitate translational and epidemiological research Setting up and maintaining a comprehensive clinical database in partnership with Rare Disease Groups. 2009-2039
See also
  Status Clinical Trial Phase
Recruiting NCT04893889 - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. N/A
Completed NCT04455230 - A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190 Phase 1/Phase 2
Completed NCT01218659 - Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease Phase 3
Completed NCT00304512 - A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease Phase 2
Withdrawn NCT04189601 - Complement Activation in the Lysosomal Storage Disorders
Completed NCT03500094 - Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) Phase 3
Withdrawn NCT04143958 - To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease Phase 4
Recruiting NCT02994303 - Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy N/A
Completed NCT01947634 - Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study. N/A
Recruiting NCT01695161 - Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer. N/A
Completed NCT01853852 - A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects Phase 1
Completed NCT00701415 - A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms Phase 3
Completed NCT00068107 - Dosing Study of Replagal in Patients With Fabry Disease Phase 2
Completed NCT01997489 - Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. Phase 4
Recruiting NCT06007768 - Autoimmune and Inflammatory Response Biomarkers in Fabry Disease
Recruiting NCT05698901 - Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
Active, not recruiting NCT03305250 - Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease N/A
Terminated NCT00526071 - Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study Phase 2
Active, not recruiting NCT03566017 - Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease Phase 3
Recruiting NCT06065605 - Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease